The European Conference on Infections in Leukaemia (ECIL-10) guidelines for COVID-19 should take convalescent plasma into proper consideration
- 4 July 2025
- journal article
- other
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2302-2303
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)Leukemia, 2025
- Convalescent plasma treatment of B-cell depleted patients with COVID-19: systematic review and individual participant data meta-analysismedRxiv, 2025
- Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trialEBioMedicine, 2025
- Sipavibart: when a success changes into a failureThe Lancet Infectious Diseases, 2025
- Serum anti‐Spike immunoglobulin G levels in random blood donors in Italy: High‐titre convalescent plasma is easier than ever to procureVox Sanguinis, 2023
- COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysisJAMA Network Open, 2023
- Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trialNature Cancer, 2022
- Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)Leukemia, 2022